Breakthrough clinical data presented at the IASLC 2025 conference reveal several promising therapeutic advances for EGFR-mutated non-small cell lung cancer (NSCLC). A bispecific antibody-drug conjugate, iza-bren, combined with osimertinib, achieved a 100% objective response rate in a Phase II study. Combination regimens pairing osimertinib with chemotherapy improved overall survival and progression-free survival, supported by findings from FLAURA2 and ACROSS 2 Phase III trials. Additionally, ivonescimab combined with chemotherapy enhanced progression-free survival post third-generation EGFR-TKI therapy, although geographic variability in drug efficacy presents regulatory challenges. Continued innovation in targeted biologics is reshaping treatment paradigms for this patient population.